Riders · Part 18: Contingency and Other Provisions · Article IX: General Provisions
Contingency for Senate Bill 2308
Rider 18.74 in the 2026-27 Act, page IX-118
Through the session
- 2024-25 Act Not in this version
- Introduced (Senate) Not in this version
- Introduced (House) Not in this version
- Senate substitute Not in this version
- House substitute Not in this version
- House passed Not in this version
- Conference New rider 18.74
- 2026-27 Act Unchanged rider 18.74
Pick any two steps to compare their wording.
What changed in the text
Conference → 2026-27 Act: the same text in both versions.
Removed words are struck through; added words are underlined. Sources: Conference · 2026-27 Act.
Every version: numbers, statuses and source pages
| Version | Rider | Against the version before | Against the current budget | Source |
|---|---|---|---|---|
| 2024-25 ActGeneral Appropriations Act, 2024-25 Biennium | Not in this version | |||
| Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) | Not in this version | |||
| Introduced (House)House Bill 1 as introduced (LBB recommended, House) | Not in this version | |||
| Senate substituteCommittee Substitute for Senate Bill 1 | Not in this version | |||
| House substituteHouse Committee Substitute for Senate Bill 1 | Not in this version | |||
| House passedSenate Bill 1 as passed the second house | Not in this version | |||
| ConferenceConference Committee Report for Senate Bill 1 | 18.74 | New | New | Page IX-119 |
| 2026-27 ActGeneral Appropriations Act, 2026-27 Biennium | 18.74 | Unchanged | New | Page IX-118 |
Full text of each wording
Conference, 2026-27 Act
Source, page IX-118Contingency for Senate Bill 2308.
(a) Contingent on enactment of Senate Bill 2308, or similar legislation relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy, by the Eighty-ninth Legislature, Regular Session, 2025, the Health and Human Services Commission is appropriated $50,000,000 from the General Revenue Fund in fiscal year 2026 in Strategy D.2.1, Community Mental Health Services, to implement the provisions of the legislation.
(b) Any unexpended balances remaining at the end of the first fiscal year of the biennium are appropriated for the same purposes for the second fiscal year of the biennium.